Asthma controller medication
Pro Research Analysisby 
Searched over 200M research papers
Asthma Controller Medication: Efficacy, Adherence, and Patient Outcomes
Introduction to Asthma Controller Medications
Asthma controller medications are essential for managing chronic asthma and preventing exacerbations. The National Asthma Education and Prevention Program recommends regular use of these medications alongside rescue medications for long-term control . Inhaled corticosteroids (ICS) are the most commonly used controller medications due to their efficacy and safety when inhaled directly into the airways . However, compliance issues, particularly among elderly and pediatric patients, can limit their effectiveness Malmstrom1999Irvin2007Shah2006.
Efficacy of Montelukast and Inhaled Corticosteroids
Montelukast as an Alternative Controller Medication
Montelukast, a leukotriene receptor antagonist, has shown clinical benefits in patients with chronic asthma. Studies indicate that montelukast is effective in both adult and pediatric populations, with a tolerability profile similar to placebo . In a placebo-controlled study, montelukast demonstrated significant improvements in asthma control compared to placebo, although no direct comparisons with inhaled corticosteroids were initially available .
Comparative Studies of Montelukast and Beclomethasone
A randomized, double-blind study compared montelukast with inhaled beclomethasone in patients requiring daily controller medication. The study found that both medications significantly improved asthma control, but montelukast offered a comparable alternative to beclomethasone, especially for patients struggling with inhaler compliance .
Theophylline and Montelukast in Poorly Controlled Asthma
Low-Dose Theophylline and Montelukast
In patients with poorly controlled asthma, adding either montelukast or low-dose theophylline to existing medications did not significantly reduce the rate of episodes of poor asthma control (EPACs) compared to placebo. However, both treatments showed small improvements in lung function . Notably, low-dose theophylline significantly improved asthma control and symptoms in patients not using inhaled corticosteroids, suggesting it as a low-cost alternative .
Combination Therapy with Inhaled Steroids
A study assessing the addition of montelukast or theophylline to inhaled steroids found that montelukast combined with budesonide resulted in greater improvements in pulmonary function compared to high-dose budesonide alone or theophylline plus budesonide . This highlights the potential benefits of combination therapy in achieving better asthma control.
Adherence to Asthma Controller Medications
Impact of Adherence on Asthma Outcomes
Adherence to asthma controller medications is crucial for preventing severe asthma exacerbations. A systematic review found that good adherence is associated with fewer severe exacerbations, emphasizing the need for strategies to improve medication adherence .
Factors Influencing Adherence
Patient nonadherence is a significant barrier to effective asthma management. Factors influencing adherence include the desire for more control over treatment, the need for immediate and long-lasting effects, and the complexity of medication regimens . Interventions such as speech recognition technology have shown promise in improving adherence among pediatric patients, demonstrating a 25.4% increase in adherence compared to usual care .
Conclusion
Asthma controller medications, including inhaled corticosteroids and montelukast, are effective in managing chronic asthma. While montelukast offers a viable alternative for patients with compliance issues, combination therapies with inhaled steroids may provide superior outcomes. Improving adherence remains a critical challenge, with innovative interventions showing potential in enhancing medication use and reducing asthma exacerbations. Future research should continue to explore strategies for optimizing asthma control and patient adherence.
Sources and full results
Most relevant research papers on this topic
Double-Blind, Randomised, Controlled Trial Assessing Controller Medications in Asthma
Adding montelukast to budesonide is safe and results in greater improvement in pulmonary function test parameters than high-dose budesonide treatment or the addition of theophylline.
Once-daily budesonide inhalation suspension for the treatment of persistent asthma in infants and young children.
Once-daily budesonide inhalation suspension is well-tolerated and effective for treating mild persistent asthma in infants and young children not adequately controlled with bronchodilators or non-GCS antiinflammatory treatments.
DOI
Factors influencing patient decisions about the use of asthma controller medication.
Patients with asthma desire more control over medication use, but lack adequate information, suggesting the need for treatment plans that allow some degree of control over medication use.
DOI